SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/MelanocortinResearch peptide

Melanotan I

aka Afamelanotide · Scenesse

α-MSH analog approved for erythropoietic protoporphyria to promote photoprotective pigmentation.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Melanotan I (afamelanotide) is a synthetic α-MSH analog approved to reduce phototoxicity in erythropoietic protoporphyria via increased eumelanin production.

Source
  • Approved pharmaceutical (afamelanotide)
Forms
  • Subcutaneous implant

Mechanism of action

Selective MC1R agonism increases melanocyte eumelanin production, providing endogenous photoprotection.

Pathways
  • · MC1R agonism
  • · Eumelanin synthesis
  • · Reduced UV-driven oxidative stress

How it acts on the body

Melanotan I is a more selective MC1R agonist than Melanotan II, with less off-target effect on MC3R, MC4R, and MC5R. The clinical use is photoprotection — in erythropoietic protoporphyria, even brief sun exposure causes severe phototoxic pain, and increased eumelanin substantially extends tolerable exposure.

Unlike unregulated 'tanning peptide' use, the licensed product is a controlled implant delivered in specialist centers with monitoring for melanocytic changes.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

Melanocortin signaling (MC1R)Increases
Selective receptor activation.
Other melanocortin receptorsStabilizes
Less off-target activity vs. Melanotan II.

Effects on the body

Increases
Eumelanin-mediated photoprotection
Decreases
Phototoxic events in EPP

Organ system effects

Skin

Primary target.

Endocrine

Melanocortin axis.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Disease-modifying option in EPP
  • Selective MC1R action

Potential side effects

Common
  • · Headache
  • · Nausea
  • · Injection-site reactions
Rare
  • · Fatigue
Serious
  • · Need for melanocytic surveillance with chronic use

Drug interactions

No notable interactions reported.

Pairing context

Often combined with
  • Standard photoprotection (clothing, sunscreen)
    Combined behavioral and pharmacologic protection.
Avoid combining with
  • History of melanoma
    Risk-benefit unfavorable.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.